Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/31251
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-02-28T11:13:04Z | - |
dc.date.available | 2023-02-28T11:13:04Z | - |
dc.date.issued | 2016-12-29 | - |
dc.identifier.citation | Ayar, Y. vd. (2017). ''Clinical outcomes and survival in AA amyloidosis patients''. Revista Brasileira de Reumatologia, 57(6), 535-544. | en_US |
dc.identifier.issn | 0482-5004 | - |
dc.identifier.uri | https://doi.org/10.1016/j.rbre.2017.02.002 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S2255502117300111 | - |
dc.identifier.uri | http://hdl.handle.net/11452/31251 | - |
dc.description.abstract | Aim: Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 +/- 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 +/- 16 months. Conclusion: Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis. | en_US |
dc.description.abstract | Resumo Objetivo: A amiloidose AA é uma complicação rara de condições inflamatórias crônicas. A maior parte dos pacientes com amiloidose AA apresenta nefropatia, que leva à insuficiência renal e à morte. Estudaram-se as características clínicas e a sobrevida em pacientes com amiloidose AA. Métodos: Analisaram-se retrospectivamente 81 pacientes (51 homens, 30 mulheres) com amiloidose AA comprovada por biópsia renal. Os pacientes foram divididos em grupos de desfecho bom e ruim de acordo com os resultados de sobrevida. Resultados: A maior parte dos pacientes (55,6%) tinha proteinúria na faixa nefrótica no momento do diagnóstico. Os distúrbios subjacentes mais frequentes foram a febre familiar do Mediterrâneo (FFM, 21,2%) e a artrite reumatoide (10,6%) no grupo de desfecho bom e a malignidade (20%) no grupo de desfecho ruim. Somente a pressão arterial diastólica no grupo de desfecho bom e o nível de fósforo no grupo de desfecho ruim foram mais elevados. Os níveis séricos de creatinina aumentaram após o tratamento em ambos os grupos, enquanto a proteinúria diminuiu no grupo de desfecho bom. O aumento na creatinina sérica e a diminuição na TFGe do grupo de desfecho ruim foram mais significativos no grupo de desfecho bom. No momento do diagnóstico, 18,5% e 27,2% de todos os pacientes tinham doença renal crônica avançada (estágios 4 e 5, respectivamente). A duração média da sobrevida renal foi de 65 ± 3,54 meses. Entre todos os pacientes, 27,1% iniciaram tratamento de diálise durante o período de seguimento e 7,4% de todos os pacientes foram submetidos a transplante renal. Níveis elevados de pressão arterial sistólica [taxas de risco (HR) 1,03, intervalo de confiança (IC) de 95%: 1 a 1,06, p = 0,036], creatinina sérica (HR 1,25, IC 95%: 1,07 a 1,46, p = 0,006) e excreção urinária de proteínas (HR 1,08, IC 95%: 1,01 a 1,16, p = 0,027) foram preditores de doença renal terminal. A mediana da sobrevida de pacientes com comprometimento de órgãos foi de 50,3 ± 16 meses. Conclusão: O presente estudo indicou que a FFM constituiu uma grande proporção de casos e crescente quantidade de pacientes com amiloidose AA idiopática. Adicionalmente, observou-se que a sobrevida do paciente não foi afetada pelas diferentes causas etiológicas na amiloidose AA. | fre |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Rheumatology | en_US |
dc.subject | AA amyloidosis | en_US |
dc.subject | Chronic kidney disease | en_US |
dc.subject | Familial mediterranean fever | en_US |
dc.subject | Mortality | en_US |
dc.subject | Renal survival | en_US |
dc.subject | Systemic amyloidosis | en_US |
dc.subject | Renal involvement | en_US |
dc.subject | Prevalence | en_US |
dc.subject | Origin | en_US |
dc.title | Clinical outcomes and survival in AA amyloidosis patients | en_US |
dc.title.alternative | Desfechos clínicos e sobrevida em pacientes com amiloidose AA | fre |
dc.type | Article | en_US |
dc.identifier.wos | 000417146600006 | tr_TR |
dc.identifier.scopus | 2-s2.0-85034596979 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-0710-0923 | tr_TR |
dc.contributor.orcid | 0000-0003-4607-9220 | tr_TR |
dc.contributor.orcid | 0000-0002-7846-0870 | tr_TR |
dc.contributor.orcid | 0000-0003-4607-9220 | tr_TR |
dc.identifier.startpage | 535 | tr_TR |
dc.identifier.endpage | 544 | tr_TR |
dc.identifier.volume | 57 | tr_TR |
dc.identifier.issue | 6 | tr_TR |
dc.relation.journal | Revista Brasileira de Reumatologia | ita |
dc.contributor.buuauthor | Ayar, Yavuz | - |
dc.contributor.buuauthor | Ersoy, Alpaslan | - |
dc.contributor.buuauthor | Öksüz, Mustafa Ferhat | - |
dc.contributor.buuauthor | Ocakoğlu, Gökhan | - |
dc.contributor.buuauthor | Vuruşkan, Berna Aytaç | - |
dc.contributor.buuauthor | Yıldız, Abdülmecit | - |
dc.contributor.buuauthor | Işıktaş, Emel | - |
dc.contributor.buuauthor | Oruç, Ayşegül | - |
dc.contributor.buuauthor | Çelikçi, Sedat | - |
dc.contributor.buuauthor | Arslan, İsmail | - |
dc.contributor.buuauthor | Şahin, Ahmet Bilgehan | - |
dc.contributor.buuauthor | Güllülü, Mustafa | - |
dc.contributor.researcherid | AAH-5180-2021 | tr_TR |
dc.contributor.researcherid | AAH-5054-2021 | tr_TR |
dc.contributor.researcherid | AAH-4002-2021 | tr_TR |
dc.contributor.researcherid | GSE-0029-2022 | tr_TR |
dc.contributor.researcherid | O-9948-2015 | tr_TR |
dc.contributor.researcherid | AAM-4927-2020 | tr_TR |
dc.contributor.researcherid | AAH-9746-2021 | tr_TR |
dc.contributor.researcherid | AGF-0767-2022 | tr_TR |
dc.identifier.pubmed | 29173691 | tr_TR |
dc.subject.wos | Rheumatology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.contributor.scopusid | 55860143300 | tr_TR |
dc.contributor.scopusid | 35612977100 | tr_TR |
dc.contributor.scopusid | 56016440100 | tr_TR |
dc.contributor.scopusid | 15832295800 | tr_TR |
dc.contributor.scopusid | 56527372000 | tr_TR |
dc.contributor.scopusid | 56256977500 | tr_TR |
dc.contributor.scopusid | 25654785700 | tr_TR |
dc.contributor.scopusid | 55133912100 | tr_TR |
dc.contributor.scopusid | 56497114200 | tr_TR |
dc.contributor.scopusid | 7004617712 | tr_TR |
dc.contributor.scopusid | 57188809248 | tr_TR |
dc.contributor.scopusid | 6602684544 | tr_TR |
dc.subject.scopus | AL Amyloidosis; Cardiomyopathies; Melphalan | en_US |
dc.subject.emtree | AA amyloidosis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Chronic kidney failure | en_US |
dc.subject.emtree | Clinical outcome | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Diastolic blood pressure | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | End stage renal disease | en_US |
dc.subject.emtree | Estimated glomerular filtration rate | en_US |
dc.subject.emtree | Familial Mediterranean fever | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Hemodialysis | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Kidney transplantation | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Proteinuria | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Rheumatoid arthritis | en_US |
dc.subject.emtree | Survival | en_US |
dc.subject.emtree | Urinary excretion | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Phosphorus | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ayar_vd_2017.pdf | 744.29 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License